Lenvatinib (Lenvima)
New oral anticancer drug Lenvima (lenvatinib) has recently been approved by Japan for the treatment of unresectable thyroid cancer. This is another important market that the drug has captured since it was approved by the United States in February of this year. Previously, lenvatinib was granted orphan drug status and priority review qualifications in the United States, Japan, and the European Union. The drug, as an innovative drug with significant public health benefits, will help address the severe unmet medical needs in the field of cancer tiroidian.
Eisai a spus că Lenvima va deveni noul standard pentru tratamentul clinic al cancerului tiroidian nerezecabil. Industria este foarte optimistă cu privire la Lenvima și se așteaptă ca medicamentul să devină o nouă vacă de bani pentru Eisai, cu vânzări anuale de peste 1 miliard de dolari.
According to Eisai’s official information, in a large phase III SELECT study, lenvatinib significantly prolonged the progression-free survival of radioiodine-refractory differentiated thyroid cancer compared to placebo (PFS: 18.3 months vs 3.6 months At the same time, a significantly higher proportion of patients in the lenvatinib treatment group achieved tumoare volume reduction (65% vs 2%). In addition, in another phase II study in Japan, lenvatinib also showed good efficacy and tolerance for medullary thyroid cancer and undifferentiated thyroid cancer.
Based on these results, Lenvima was approved by the Japanese regulatory agency to become the first molecular targeted therapy for unresectable thyroid cancer (including differentiated thyroid cancer, medullary thyroid cancer, and undifferentiated thyroid cancer).
În prezent, deși majoritatea tipurilor de cancer tiroidian pot fi tratate, există puține opțiuni de tratament odată ce acesta se agravează. Cancerul tiroidian diferențial (DTC) este cea mai frecventă tumoare malignă tiroidiană, iar incidența sa a crescut constant în ultimii ani.
Lenvatinib este un inhibitor oral multireceptor de tirozin kinaza (RTK) cu un nou mod de legare. În plus față de inhibarea altor RTK implicate în proliferarea tumorii și căile de semnalizare oncogene, poate, de asemenea, inhiba selectiv activitatea kinazei receptorului factorului de creștere endotelial vascular (VEGF).
